An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study. (2019). SKIN The Journal of Cutaneous Medicine, 3, S12. https://doi.org/10.25251/skin.3.supp.12